<DOC>
	<DOCNO>NCT02442206</DOCNO>
	<brief_summary>This mechanistic study single-center , randomize , double-blind , placebo-controlled , cross-over study evaluate effect dual bronchodilation QVA149 cardiac lung function parameter hyperinflated COPD patient .</brief_summary>
	<brief_title>Effect QVA149 ( Indacaterol Maleate/Glycopyrronium Bromide ) Cardiac Function COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Patients airflow limitation indicate postbronchodilator FEV1 &lt; 80 % predict normal value postbronchodilator FEV1/FVC &lt; 0.7 Current exsmokers smoke history least 10 pack year . Able willing give write informed consent Hyperinflated patient RVol &gt; 135 % predict Patients LABA LAMA treatment Visit 1 . History one COPD exacerbation require treatment antibiotic , systemic steroid ( oral intravenous ) hospitalization 3 month prior Visit 2 . More one COPD exacerbation require treatment antibiotic , systemic steroid ( oral intravenous ) hospitalization within 6 month prior Visit 2 . Patients clinically significant cardiovascular abnormality , could interfere assessment study treatment ( limited cardiac arrhythmia , heart failure leave ventricular ejection fraction &lt; 40 % determine MRI scan , unstable ischemic heart disease , NYHA Class III/IV leave ventricular failure , history myocardial infarction 6 month prior Visit 2 ) Patients know history current atrial fibrillation confirm ECG . Patients pacemaker , bypass stent . Patients whose QTcF measure Visit 3 &gt; 450 m male &gt; 470 m female Additional studyspecific inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>QVA149 , cardiac function , ventricular enddiastolic volume , hyperinflated COPD patient</keyword>
</DOC>